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Mutations at tyrosine 641 (Y641F, Y641N, Y641S and Y641H) in the SET domain of EZH2 have been
identiﬁed in patients with certain subtypes of non-Hodgkin lymphoma (NHL). These mutations were
shown to change the substrate speciﬁcity of EZH2 for various methylation states of lysine 27 on his-
tone H3 (H3K27). An additional mutation at EZH2 Y641 to cysteine (Y641C) was also found in one
patient with NHL and in SKM-1 cells derived from a patient with myelodisplastic syndrome
(MDS). The Y641C mutation has been reported to dramatically reduce enzymatic activity. Here, we
demonstrate that while the Y641C mutation ablates enzymatic activity against unmethylated and
monomethylated H3K27, it is superior to wild-type in catalyzing the formation of trimethylated
H3K27 from the dimethylated precursor.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
EZH2 is the catalytic subunit of the Polycomb-Repressive Com-
plex 2 (PRC2), which is responsible for the mono- through trime-
thylation of lysine 27 on histone H3 (H3K27) [1,2]. Of these
methylation states, trimethylated H3K27 (H3K27me3) is associ-
ated with the repression of gene transcription. Physiologically,
H3K27me3 establishment and maintenance is important during
processes such as X-inactivation, germline development and stem
cell pluripotency [3]. While PRC2 activity is fundamental to cellular
development and differentiation, its misregulation has been impli-
cated in oncogenesis and metastasis, and correlates negatively
with patient survival. In particular, overexpression of EZH2 or
other subunits of the PRC2 complex has been identiﬁed as a driver
of lymphomagenesis [4,5] and has been linked to solid tumors of
the prostate, breast, ovaries, colon, bladder, liver and skin [6–11].
In addition, loss-of-function mutations in the correspondingchemical Societies. Published by E
S, myelodisplastic syndrome;
lymphoma; GCB, germinal-
ma; WT, wild-type; SAM,H3K27 demethylase, UTX, have also been reported in a variety of
blood and solid cancers [12].
From a diverse set of studies, a common understanding of the
role of PRC2 function in tumorigenesis has emerged; the overarch-
ing hypothesis today is that mechanisms leading to elevation of
H3K27me3 levels result in transcriptional silencing of tumor sup-
pressor genes that in turn result in malignancy. Additional support
for this notion comes from a recent report of detailed biochemical
characterization of heterozygous somatic mutations at tyrosine
641 within the catalytic SET domain of EZH2 (Y641F, Y641N,
Y641S, Y641H) in follicular lymphoma (FL) and the germinal-cen-
ter B-cell-like (GCB) subtype of diffuse large B-cell lymphoma
(DLBCL) [13]. These mutations were originally designated as loss-
of-function mutations based on a marked reduction in the ability
of the mutant enzymes to methylate an unmodiﬁed peptide sub-
strate bracketing the K27 site of H3. Further analysis demonstrated
that the Y641 mutants of EZH2 dramatically altered the substrate
speciﬁcity of the enzyme with respect to methylation state of the
H3K27 residue [2,14]. The wild-type (WT) enzyme is most proﬁ-
cient at performing the initial monomethylation reaction at
H3K27 and is consecutively less proﬁcient at catalyzing the mono-
methyl to dimethyl and dimethyl to trimethyl reactions. In
contrast, the NHL-associated mutant enzymes all displayed the
opposite pattern of substrate utilization; these enzymes were
essentially inactive as catalysts of the initial monomethylationlsevier B.V. All rights reserved.
3012 T.J. Wigle et al. / FEBS Letters 585 (2011) 3011–3014reaction, but showed increasing activity as dimethyltransferases
and trimethyltransferases. It was concluded that robust elevation
of the H3K27me3mark that is an epigenetic signature of these can-
cers would result from enzymatic coupling between the WT and
mutant EZH2 enzymes in the context of heterozygous NHL patient
cells. The pattern of mono-, di- and trimethylated H3K27 found in
heterozygous NHL patient-derived cell lines was well predicted by
calculations based on the proposed enzymatic coupling between
WT and mutant EZH2 [2].
Tyrosine 641 of EZH2 has been found to be mutated to cysteine
(Y641C) in one patient with DLBCL [13]. This mutation was also ob-
served to be heterozygous, but due to its low frequency (2%) rela-
tive to the other four mutations found (13–49%), it was not
investigated further Recently, an EZH2 Y641C mutation was also
found in SKM-1 cells derived from a patient afﬂicted with myelo-
displastic syndrome (MDS) [15,16], and again enzyme assays of
puriﬁed PRC2 incorporating this EZH2 mutant indicated that it
had signiﬁcantly reduced activity against an unmodiﬁed peptide
substrate [15]. In light of the biochemical changes in activity seen
with other Y641 mutations of EZH2, we were motivated to better
understand the Y641C mutant. Here we report that the tyrosine
to cysteine substitution at residue 641 of EZH2 prevents the ability
of the enzyme to mono- or dimethylate the H3K27 residue. How-
ever the Y641C mutant demonstrates signiﬁcant activity in cata-
lyzing the ﬁnal step of taking H3K27me2 and adding another
methyl group to form the H3K27me3 product. This pattern of sub-
strate utilization for the Y641C mutant is different from that ob-
served for the EZH2 variants thus far identiﬁed in association
with human disease.
2. Materials and methods
Recombinant 4-component PCR2 was produced in Spodoptera
frugiperda (Sf9) cells using a baculovirus expression system.
Wild-type EZH2 (NM_004456) was coexpressed with wild-type
FLAG-EED (NM_003797), SUZ12 (NM_015355), and RbAp48
(NM_005610). An N-terminal FLAG tag on the EED was used to
purify active PRC2 complex from cell lysates. For production of
mutant 4-component PCR2, EZH2 carrying the Y641C mutation
was co-expressed with wild-type His-FLAG-tagged EED
(NM_003797), His-tagged SUZ12 (NM_015355) and His-tagged
RbAp48 (NM_005610), again using the baculovirus system. The
His- and FLAG-tags were used for puriﬁcation. The purity of the ﬁ-
nal PRC2 preparations was assessed by SDS–PAGE with Coomassie
blue staining and microﬂuidic capillary electrophoresis (Agilent
Bioanalyzer). We have data (not shown in this paper) that the mu-
tant complexes puriﬁed with the EED-FLAG or EED-FLAG-His,
EZH2-His, Suz12-His and RbAp48-His tags have identical substrate
speciﬁcity and enzyme kinetics. Peptide substrates representativeFig. 1. Progress curves for incorporation of a tritiated methyl groups into H3K27 peptid
EZH2. 8 nM total enzyme was used in the reactions and the biotinylated peptide susbtrat
was measured in counts per minute (cpm). (C) Enzyme velocities of PRC2 complexes con
representing the standard deviation of three experiments.of histone H3 residues 21–44 containing either un-, mono-, di- or
trimethylated lysine 27 and a C-terminal biotin (appended to a
C-terminal amide-capped lysine) were HPLC-puriﬁed to greater
than 95% purity. The enzyme assay was performed as previously
described [2]. K1/2 values for the peptide were calculated using
Kaleidagraph 4.0 and Michaelis–Menten Km values for SAM were
calculated using GraphPad Prism 5.0.
The sequencing of SKM-1 cells was performed on 5 million cells
in linear log growth phase that were collected, washed in PBS, and
snap frozen. Genomic DNA was then extracted from the frozen cell
pellets, and PCR ampliﬁed using optimized cycling conditions. Pri-
mer extension sequencing was performed by GENEWIZ, Inc (South
Plainﬁeld, NJ) using Applied Biosystems BigDye version 3.1. The
reactions were then run on Applied Biosystem’s 3730xl DNA Ana-
lyzer. Sequencing base calls were done using KB™ Basecaller (Ap-
plied Biosystems). Somatic Mutation calls were determined by
Mutation Surveyor (SoftGenetics) and conﬁrmed manually by
aligning sequencing data with the corresponding reference se-
quence using Seqman (DNASTAR). Sequence alignment was done
with DNADynamo software and WebLogo 3.
3. Results
The Y641C mutant of EZH2 was incorporated into a recombi-
nant PRC2 complex as previously described for other EZH2 mutant
enzymes [2], and was assessed for methyltransferase activity
against a panel of peptidic substrates present at a concentration
of 1 lMwith 200 nM S-adenosylmethionine (SAM) as the cofactor.
The peptidic substrates tested here represent the amino acid se-
quence of human histone H3 residues 21 through 44 with lysine
27 represented as the unmodiﬁed, monomethylated or dimethylat-
ed side chain amine. As a control, experiments with recombinant
PRC2-containing WT EZH2 were run simultaneously under the
same conditions as for the mutant enzyme. Fig. 1A illustrates the
product progress curves for the WT enzyme against H3K27me0,
H3K27me1 and H3K27me2 containing peptidic substrates. As pre-
viously reported, the WT enzyme displays robust activity as a
monomethyltransferase but wanes in activity when presented
with the H3K27me1 and especially the H3K27me2 substrates.
For comparison, the product progress curves for the Y641C mutant
enzyme are illustrated in Fig. 1B. A distinctly different pattern of
substrate utilization is seen for this mutant relative to the WT en-
zyme. For the mutant enzyme, only the ﬁnal dimethyl- to tri-
methyl-lysine reaction is signiﬁcantly catalyzed. The comparison
of relative activities is best illustrated in Fig. 1C where the reaction
velocities for each substrate with each enzyme are summarized.
To further understand the differences between wild-type and
mutant enzyme activity, the methylation state substrate speciﬁcity
was explored through steady-state enzyme kinetics using the samees by a recombinant PRC2 complex containing (A) wild-type EZH2 and (B) Y641C
es were captured in a scintillant-embedded microplate. The incorporation of tritium
taining either wild-type or Y641C EZH2 are summarized. All plots contain error bars
Table 1
Steady-state kinetic parameters for methylation reactions catalyzed by PRC2




K1/2 (nM) kcat (h1) kcat/K1/2
(h1 nM1  104)
Wild-type 0 157 ± 12 4.80 ± 0.20 305 ± 26
1 337 ± 26 3.33 ± 0.21 99 ± 9
2 144 ± 11 1.08 ± 0.04 75 ± 6
Y641C 0 N.M. N.M. N.M.
1 279 ± 45 0.64 ± 0.03 23 ± 3
2 185 ± 8 2.98 ± 0.25 161 ± 12
* All reactions were run with 8 nM PRC2. The WT reaction used 1.5 lM SAM and
the Y641C reaction used 4 lM SAM.
 N.M. denotes the activity was too low to quantify.
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in Table 1. The peptides displayed sigmoidal behavior and the data
were ﬁt using a K1/2 calculation rather than classic Michaelis–Men-
ten ﬁts to determine the concentration of peptide resulting in half-
maximal velocity [2,17]. In addition, the catalytic efﬁciency of the
mutant and wild-type enzymes is compared by analysis of the ratio
of kcat/K1/2 for each peptide substrate. The enzymes showed no
activity on a peptide of the same length containing trimethylated
lysine 27 (data not shown), ensuring that there was no methylation
at a lysine other than H3K27 occurring. The K1/2 values for the
wild-type enzyme reported here are within range of previously re-
ported values [2], but the kcat was consistently about 5-fold higher.
We attribute this difference in turnover rate to a new preparation
of the PRC2 complex having a higher proportion of catalytically ac-
tive enzyme. There was no detectable activity of the Y641C mutant
enzyme on the unmethylated peptide substrate, even at the high-
est concentrations of peptide tested (3 lM).
There is a discordance in the literature and the COSMIC data-
base over the status of the Y641C mutation in the SKM-1 cell line;
Ernst et al. describe it as being homozygous [15], while the COSMIC
database indicates that it is heterozygous [16]. To rectify these
conﬂicting results, we conducted an independent sequencing anal-
ysis of SKM-1 cells, and indeed conﬁrmed that the Y641C mutation
is heterozygous (Fig. 3). This ﬁnding is in agreement with the data
seen previously with the other Y641 mutants [2,13] and supports
the hypothesis that heterozygous mutations are required for the
coordinated activities of wild-type and mutant enzymes in
pathogenesis.
4. Discussion
The pattern of substrate utilization by the Y641Cmutant is rem-
iniscent of that seen for other Y641 mutations of EZH2, in that the
ﬁrst reaction is essentially not catalyzed by the mutant enzyme,Fig. 2. How different peptide substrate methylation states inﬂuences: (A) the K1/2, the con
the catalytic efﬁciency, deﬁned by the kcat to K1/2 ratio. Symbol legend: wild-type EZH2the intermediate mono- to dimethyl reaction is modestly catalyzed
and the ﬁnal dimethyl to trimethyl reaction is robustly catalyzed.
However, a subtle distinction is realized by inspection of Fig. 1C
and Table 1. With the exception of EZH2 Y641F, the previously re-
ported Y641 mutant EZH2 variants all demonstrated robust dim-
ethyltransferase activity (i.e., catalyzing the H3K27me1 to
H3K27me2 reaction at approximately 50% the velocity of WT en-
zyme) [2], while the Y641C mutant appears to be considerably
weaker at catalyzing this intermediate reaction. However, despite
the similarities in catalytic efﬁciencies for monomethylation and
dimethylation that distinguish the Y641F and Y641C mutants from
the others, they are differentiated by their ability to catalyze the
trimethylation reaction. Like the other mutants, the Y641F mutant
is markedly improved over wild-type as a trimethylase (>10-fold
activity relative to wild-type), while the Y641C mutant is only
roughly 2-fold improved over wild-type in this respect.
In Fig. 2, we examine how the catalytic efﬁciency of the mutant
and wild-type enzymes is affected by the methylation status of the
target lysine. The K1/2, kcat and the kcat to K1/2 ratio are plotted as a
function of the number of methyl groups on H3K27. Inspection of
the K1/2 plot reveals that the wild-type and Y641C mutant enzymes
display similar afﬁnities for the mono- and dimethyl peptide sub-
strate as measured by the K1/2 (Fig. 2A). Where the enzymes are
noticeably different is in the rates of catalysis stimulated by the
different methylation states of the substrate peptide. The enzymes
have maximal reaction velocities trending in opposite directions as
lysine 27 goes fromme0 to me1 to me2. Whereas the wild-type en-
zyme shows a diminution in kcat as the peptide goes to the di-
methyl state, the Y641C mutant displays increasing kcat (Fig. 2B).
The catalytic efﬁciency, measured by the K1/2 to kcat ratio also fol-
lows a pattern similar to the kcat (Fig. 2C), implying that like the
other Y641 mutants, the Y641C mutant differs from the wild-type
enzyme with respect to transition state recognition [2]. This is con-
sistent with the concept that EZH2 Y641 mutations [2], and analo-
gous SET domain mutations shown in SET7/9 [18] and G9a [19],
alleviate steric crowding of the target lysine in the active site. This
small change presumably accommodates a bulkier dimethyl lysine
and induces a change of function that sees EZH2 act primarily as a
trimethyltransferase rather than as a monomethyltransferase.
In addition, the Y641C steady-state Km for SAM utilization on
the preferred substrate is about 2.7-fold greater (4 lM vs.
1.5 lM) than the measured Km values for the wild-type or other
Y641 mutants, although the kcat values are within two-fold of each
other. Taken together with the peptide kinetic data, the extent to
which effective coupling between WT and Y641C mutant EZH2
may occur in a heterozygous lymphoma cell to elevate the produc-
tion of the H3K27me3 product is unclear. This may explain the low
frequency of occurrence of this mutant in lymphoma. Further
studies will be required to assess the effectiveness of enzymatic
coupling with this and other EZH2 mutants.centration of peptide stimulating half-maximal enzyme velocity, (B) the kcat and (C)
(s) and Y641C EZH2 (j).
Fig. 3. Sequencing of the SKM-1 cell line indicates that it is heterozygous for the
EZH2 Y641C mutation, conﬁrming the mutation status that is reported in the
COSMIC database.
3014 T.J. Wigle et al. / FEBS Letters 585 (2011) 3011–3014The results presented in this communication clearly demon-
strate that, contrary to earlier reports, the Y641C mutant of EZH2
retains signiﬁcant, albeit altered catalytic activity as an H3K27
methyltransferase. As with the previously studied Y641 mutants
of EZH2, the Y641C mutant is most effective as a trimethyltransfer-
ase and least effective as a monomethyltransferase. The implica-
tions of this altered substrate speciﬁcity for EZH2 Y641C in
human disease remain to be determined through further biochem-
ical and cell biological characterization.
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